{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:16:18Z","timestamp":1784236578466,"version":"3.55.0"},"reference-count":0,"publisher":"Dustri-Verlgag Dr. Karl Feistle","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.5414\/cn109927letter","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T08:23:43Z","timestamp":1580459023000},"page":"307-309","source":"Crossref","is-referenced-by-count":8,"title":["Doubts about the efficacy of tolvaptan for polycystic kidney disease"],"prefix":"10.5414","volume":"93","author":[{"given":"Clark L.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3374","container-title":["Clinical Nephrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T09:30:38Z","timestamp":1589362238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dustri.com\/article_response_page.html?artId=186206&doi=10.5414\/CN109927Letter&L=0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"alternative-id":["109927"],"URL":"https:\/\/doi.org\/10.5414\/cn109927letter","relation":{},"ISSN":["0301-0430"],"issn-type":[{"value":"0301-0430","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}